Money committed to study of dyskinesia - Michael J. Fox Foundation for Parkinson's Research - Brief Article

AORN Journal, June, 2003

The Michael J. Fox Foundation for Parkinson's Research has committed $2 million to a new research initiative to study dyskinesia, according to a Feb 7, 2003, news release from the organization. Dyskinesia is the involuntary, uncontrollable movements that are a frequent side effect of the treatment of Parkinson's disease. It is distinct from the tremors commonly associated with the disease and a major limiting factor in achieving adequate long-term control of Parkinson's symptoms.

The most commonly used medicine for the treatment of Parkinson's disease is levodopa, frequently called L-dopa. This medication helps restore levels of dopamine, a chemical messenger in the brain that is responsible for smooth, coordinated movement and other motor functions. After five to 10 years of treatment with L-dopa, however, approximately 80% of patients with Parkinson's disease develop dyskinesia, which becomes a major source of disability. Dyskinesia also can develop in patients who do not take L-dopa.

Experts feel that gaining an understanding of the mechanisms of dyskinesia would be a major breakthrough that would produce an immediate effect on the day-to-day lives of patients with Parkinson's disease. They are seeking a broad-based approach that includes

* understanding the mechanisms of dyskinesia at the molecular level,

* testing the effect of interventions on the neuroanatomical and neurophysiological substrates of dyskinesia,

* exploring the mechanisms of various subtypes of dyskinesia,

* developing animal models, and

* seeking novel therapies, both preventive and ameliorative.

The Michael J, Fox Foundation for Parkinson's Research Commits $2 Million to Study PD Dyskinesia (news release, New York: The Michael J. Fox Foundation for Parkinson's Research, Feb 7, 2003) http://www.michael jfox.org/news/pressrelease.php?id=44 (accessed 10 Feb 2003).